Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ATHERSYS, INC / NEWATHX · Entity 95922 | Director | January 09, 2023 | January 11, 2023 |
| Acorda Therapeutics, Inc.ACOR · Entity 111987 | President, Intl and GC | December 02, 2019 | December 04, 2019 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 15, 2026 | May 20, 2026 |
| SELLAS Life Sciences Group, Inc.SLS · Entity 4313 | Director | January 07, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ATHERSYS, INC / NEW
Report date January 09, 2023 · Filed January 11, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,141 |
Reported balance
After 2023-01-09 transaction · row 1
1 source rowRow 1 · 2023-01-09 · Grant · Acquired 22,321 · Balance 35,141 F1: Represents the exempt acquisition of 22,321 restricted stock units that in general will vest in total on June 30, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the exempt acquisition of 22,321 restricted stock units that in general will vest in total on June 30, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors.
Acorda Therapeutics, Inc.
Report date December 02, 2019 · Filed December 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,420 |
Reported balance
After 2019-12-02 transaction · row 1
1 source rowRow 1 · 2019-12-02 · Sale · Disposed 2,227 · Balance 117,420 F1: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $1.53 to $1.68 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $1.53 to $1.68 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
RIGEL PHARMACEUTICALS INC
Report date May 15, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,250 |
Reported balance
After 2026-05-15 transaction · row 1
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 5,750 · Balance 18,250 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
SELLAS Life Sciences Group, Inc.
Report date January 07, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,900 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 50,000 · Balance 92,900 F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 20, 2026 00:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002535 · form4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,250 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| January 07, 2026 Filed Jan 9, 2026 21:30 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-002491 · tm262627-1_4seq1.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,900 F1 · shares: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 30, 2025 Filed Jun 2, 2025 20:42 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | PurchaseCommon Stock | 20,000 | $1.69 | $33,800.00 |
DisclosureSEC source: 0001104659-25-055495 · tm2516957-1_4seq1.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,400 F1 · price: The shares were purchased in multiple transactions at a price of $1.69. The reporting person undertakes to provide SELLAS Life Sciences Group, Inc., any security holder of SELLAS Life Sciences Group, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at the price set forth in this footnote. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $18.95 | $0.00 |
DisclosureSEC source: 0000905148-25-001936 · form4.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2035-05-23 F3 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:27 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001936 · form4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. F2 · balance_after: This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:33 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001104659-25-003498 · tm253166-5_4seq1.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2035-01-10 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 10, 2026 (the first anniversary of the date of grant) or (y) the business day prior to the 2026 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 10, 2025 Filed Jan 14, 2025 22:33 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-003498 · tm253166-5_4seq1.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,900 F1 · shares: The Reporting Person received an award of 12,500 restricted stock units on January 10, 2025, which shall vest in full on December 1, 2025, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 25, 2024 Filed May 29, 2024 23:21 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0000905148-24-001656 · form4.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-05-25 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 25, 2024 Filed May 29, 2024 23:21 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001656 · form4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 11:02 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001104659-24-006397 · tm243935-8_4seq1.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-01-22 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 22, 2025 (the first anniversary of the date of grant) or (y) the business day prior to the 2025 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 11:02 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-006397 · tm243935-8_4seq1.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,400 F1 · shares: The Reporting Person received an award of 6,000 restricted stock units on January 22, 2024, which shall vest in full on December 1, 2024, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001140361-23-034288 · form4.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-05-26 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 26, 2023 Filed Jul 12, 2023 22:45 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-034288 · form4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:13 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 9,500 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0001104659-23-010629 · tm235353d4_4seq1.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Common Stock · 9,500 shares Expires 2033-02-02 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) February 2, 2024 (the first anniversary of the date of grant) or (y) the business day prior to the 2024 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:13 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-010629 · tm235353d4_4seq1.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 F1 · shares: The Reporting Person received an award of 2,500 restricted stock units on February 2, 2023, which shall vest in full on December 1, 2023, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 17:30 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantCommon Stock | 22,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001368148-23-000017 · wf-form4_167345822333784.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,141 F1 · shares: Represents the exempt acquisition of 22,321 restricted stock units that in general will vest in total on June 30, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 17:39 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantStock Option (right to purchase) · Derivative | 32,042 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0001368148-22-000131 · wf-form4_166369556053492.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,084 Underlying: Common Stock · 32,042 shares Expires 2032-09-16 F3 · derivative.exercise_date: Represents the exempt acquisition of stock options to purchase 32,042 shares of the Issuer's Common Stock at a per share exercise price of $1.95. These stock options in general will vest on July 28, 2023, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 17:39 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantCommon Stock | 12,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001368148-22-000131 · wf-form4_166369556053492.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,820 F1 · shares: Represents the exempt acquisition of 12,820 restricted stock units that in general will vest in total on December 31, 2022, subject generally to the Reporting Person's continued service on the Issuer's Board of Directors. F2 · balance_after: On August 26, 2022, the Issuer effected a 1-for-25 reverse stock split of its Common Stock (the "Reverse Stock Split"). Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001140361-22-020307 · form4.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-05-20 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:50 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-020307 · form4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 22:07 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 7,125 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001104659-22-010400 · tm225088-6_4seq1.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 7,125 shares Expires 2032-01-31 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 31, 2023 (the first anniversary of the date of grant) or (y) the business day prior to the 2023 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| January 31, 2022 Filed Feb 1, 2022 22:07 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantCommon Stock | 1,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-010400 · tm225088-6_4seq1.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F1 · shares: The Reporting Person received an award of 1,900 restricted stock units on January 31, 2022, which shall vest in full on December 1, 2022, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| June 15, 2021 Filed Jun 15, 2021 21:39 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantNonQualified Stock Option (right to purchase) · Derivative | 50,000 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001368148-21-000066 · wf-form4_162379312322561.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: Award of a nonqualified stock option. The option vests ratably on a quarterly basis over a one-year period. Read SEC document |
| May 19, 2021 Filed May 22, 2021 01:03 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.64 | $0.00 |
DisclosureSEC source: 0001179110-21-005769 · edgar.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-05-19 F2 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| May 19, 2021 Filed May 22, 2021 01:03 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-005769 · edgar.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:29 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001104659-21-033298 · tm218923d5_4.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-03-04 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 4, 2022 (the first anniversary of the date of grant) or (y) the business day prior to the 2022 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 20:44 UTC | ATHERSYS, INC / NEW ATHX · Entity 95922 | GrantNonQualified Stock Option (right to purchase) · Derivative | 100,000 | $0.00 Strike: $1.88 | $0.00 |
DisclosureSEC source: 0001368148-20-000133 · wf-form4_160555945689038.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-11-12 F1 · derivative.exercise_date: Award of a nonqualified stock option. The option vests one-third on the one-year anniversary date from the date of grant, and the remainder vests on a quarterly basis over years two and three. Read SEC document |
| May 15, 2020 Filed May 16, 2020 00:56 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001179110-20-006135 · edgar.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The shares vest monthly over one (1) year from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| March 12, 2020 Filed Mar 17, 2020 01:20 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $1.89 | $0.00 |
DisclosureSEC source: 0001104659-20-034290 · tm2012902-6_form4.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2030-03-12 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 12, 2021 (the first anniversary of the date of grant) or (y) the business day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 07:53 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 2,227 | $1.60 | $3,552.73 |
DisclosureSEC source: 0001209191-19-058939 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,420 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $1.53 to $1.68 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 08:17 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.41 | $0.00 |
DisclosureSEC source: 0001209191-19-055909 · doc4.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-11-07 F1 · derivative.exercise_date: Options issued under the issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to the options vest in equal quarterly installments over two years beginning on November 7, 2019 with the first quarterly installment vesting on February 7, 2020. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:18 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001179110-19-006700 · edgar.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 13,750 shares Expires 2029-05-23 F1 · derivative.exercise_date: The shares shall vest monthly over one (1) year) from the date of grant subject to the reporting person's continuous service on the Company's Board of Directors. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 22:36 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option ( Right to Buy) · Derivative | 80,000 | $0.00 Strike: $2.42 | $0.00 |
DisclosureSEC source: 0001179110-19-004740 · edgar.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-04-01 F1 · derivative.exercise_date: The Option shall vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the director is appointed to the Board and ending on the date of the annual meeting at which the director is first considered for election by the stockholders, provided that the non-employee director continues to provide services. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 23:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0000899243-19-008206 · doc4.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-03-14 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 14, 2020 (the first anniversary of the date of grant) or (y) the day prior to the 2020 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 16:25 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantEmployee Stock Option (right to buy) · Derivative | 21,355 | $0.00 Strike: $13.51 | $0.00 |
DisclosureSEC source: 0001209191-19-018799 · doc4.xml · derivative · entry 2 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,355 Underlying: Common Stock · 21,355 shares Expires 2029-03-08 F2 · derivative.exercise_date: Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019 with the first quarterly installment vesting on April 1, 2019. Read SEC document |
| March 08, 2019 Filed Mar 12, 2019 16:25 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 12,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-018799 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,647 F1 · shares: Restricted shares issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares will vest 25% every year for four years with vest dates of December 1, 2019, December 1, 2020, December 1, 2021 and December 1, 2022. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 16:21 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 953 | $13.38 | $12,751.14 |
DisclosureSEC source: 0001209191-19-012980 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,834 F1 · shares: Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4. Read SEC document |
| December 22, 2018 Filed Dec 27, 2018 08:16 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-064144 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,787 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 08:42 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 3,067 | $20.52 | $62,947.41 |
DisclosureSEC source: 0001209191-18-061119 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,287 F1 · shares: Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from equity vesting. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.0500 to $20.7900 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 05, 2018 Filed Nov 7, 2018 16:13 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 955 | $20.28 | $19,367.40 |
DisclosureSEC source: 0001209191-18-057560 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,354 F1 · shares: Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4. Read SEC document |
| September 10, 2018 Filed Sep 12, 2018 16:21 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-050640 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,309 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 22:31 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001209191-18-037551 · doc4.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2028-06-11 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) June 12, 2019 (the first anniversary of the date of grant) or (y) the day prior to the 2019 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document |
| March 13, 2018 Filed Mar 16, 2018 00:03 UTC | SELLAS Life Sciences Group, Inc. SLS · Entity 4313 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $5.24 | $0.00 |
DisclosureSEC source: 0001209191-18-020021 · doc4.xml · derivative · entry 1 Wasman Jane · CIK 0001352455 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-03-12 F1 · derivative.exercise_date: The option shares will vest and became exercisable in equal monthly installments for thirty-six (36) months following the March 13, 2018 grant date, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. Read SEC document |
| March 08, 2018 Filed Mar 12, 2018 08:40 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 2,470 | $25.65 | $63,355.50 |
DisclosureSEC source: 0001209191-18-018703 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,809 F1 · shares: Reflects the number of shares of the issuer's Common Stock that were withheld to cover tax liability in connection with settlement of restricted stock units that vested as reported on a prior Form 4. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 07:54 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,980 | $0.00 Strike: $19.81 | $0.00 |
DisclosureSEC source: 0001209191-18-017582 · doc4.xml · derivative · entry 3 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,980 shares Expires 2018-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. F2 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 01/01/2012. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 07:54 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Tax withholdingCommon Stock | 2,274 | $25.95 | $59,010.30 |
DisclosureSEC source: 0001209191-18-017582 · doc4.xml · nonDerivative · entry 2 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,279 Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 07:54 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionCommon Stock | 2,980 | $19.81 | $59,033.80 |
DisclosureSEC source: 0001209191-18-017582 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,553 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 08:42 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | GrantCommon Stock | 6,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013213 · doc4.xml · nonDerivative · entry 1 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,573 F1 · shares: Reflects the number of shares of the issuer's Common Stock that will be issued to the reporting person based on the vesting of restricted stock units that were previously awarded to the reporting person. The vesting of the shares under the restricted stock units was based on the issuer's achievement of a performance milestone that was specified at the time the restricted stock units were awarded. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 07:52 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 34,520 | $0.00 Strike: $19.81 | $0.00 |
DisclosureSEC source: 0001209191-18-004824 · doc4.xml · derivative · entry 4 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,980 Underlying: Common Stock · 34,520 shares Expires 2018-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. F4 · derivative.exercise_date: The shares subject to these options vested in installments and were fully vested on 1/01/2012. Read SEC document |
| January 19, 2018 Filed Jan 23, 2018 07:52 UTC | Acorda Therapeutics, Inc. ACOR · Entity 111987 | SaleCommon Stock | 350 | $28.63 | $10,020.01 |
DisclosureSEC source: 0001209191-18-004824 · doc4.xml · nonDerivative · entry 3 Wasman Jane · CIK 0001352455 · President, Intl and GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,110 F1 · shares: Exercise and sales pursuant to a 10b5-1 plan. The exercised options were scheduled to expire in 2018 on the expiration date reported within Table II unless exercised. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $28.60 to $28.80 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.